193 related articles for article (PubMed ID: 30394560)
21. First experience of using Brentuximab vedotin and modified program NHL-BFM-90 in the front-line treatment of patient with anaplastic large-cell lymphoma: a case report and a review of literature.
Chernova NG; Zvonkov EE; Badmazhapova DS; Sinitsyna MN; Grebenyuk LA; Sidorova YV; Kostina IE; Kovrigina AM; Obukhova TN; Sudarikov AB; Savchenko VG
Ter Arkh; 2018 Aug; 90(7):77-81. PubMed ID: 30701926
[TBL] [Abstract][Full Text] [Related]
22. Co-existent primary cutaneous anaplastic large cell lymphoma and lymphomatoid papulosis.
Dawn G; Morrison A; Morton R; Bilsland D; Jackson R
Clin Exp Dermatol; 2003 Nov; 28(6):620-4. PubMed ID: 14616830
[TBL] [Abstract][Full Text] [Related]
23. Blastic plasmacytoid dendritic cell neoplasm with response to pralatrexate.
Sato S; Tanaka E; Tamai Y
Ann Hematol; 2019 Mar; 98(3):801-803. PubMed ID: 30652209
[No Abstract] [Full Text] [Related]
24. Cutaneous involvement in systemic anaplastic large cell lymphoma.
Kwok C; Salmo E
J Dtsch Dermatol Ges; 2015 Jul; 13(7):693-5. PubMed ID: 26031654
[No Abstract] [Full Text] [Related]
25. Recurrent posterior reversible encephalopathy syndrome after chemotherapy in hematologic malignancy-posterior reversible encephalopathy syndrome can strike twice!!!
Roy S; Gandhi AK; Jana M; Julka PK
J Cancer Res Ther; 2014; 10(2):393-6. PubMed ID: 25022403
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma.
Dunleavy K; Pittaluga S; Shovlin M; Roschewski M; Lai C; Steinberg SM; Jaffe ES; Wilson WH
Haematologica; 2016 Jan; 101(1):e27-9. PubMed ID: 26518748
[No Abstract] [Full Text] [Related]
27. Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma.
Nijland M; van Meerten T; Seitz A; Huls G; Kibbelaar R; Visser L; van den Berg A; Diepstra A
Ann Hematol; 2018 May; 97(5):905-907. PubMed ID: 29327077
[No Abstract] [Full Text] [Related]
28. Successful rapid desensitization to the antibody-drug conjugate brentuximab vedotin in a patient with refractory Hodgkin lymphoma.
Fizesan M; Boin C; Aujoulat O; Newinger G; Ghergus D; Watier H; Lustig H; Ojeda-Uribe M
J Oncol Pharm Pract; 2016 Feb; 22(1):188-92. PubMed ID: 25586990
[No Abstract] [Full Text] [Related]
29. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma.
Akpek G; Koh HK; Bogen S; O'Hara C; Foss FM
Cancer; 1999 Oct; 86(7):1368-76. PubMed ID: 10506727
[TBL] [Abstract][Full Text] [Related]
30. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
31. HIV-related lymphoma treated with maintenance thalidomide.
Larson ML; Enschede SH; Gregory SA
Clin Adv Hematol Oncol; 2005 Mar; 3(3):231-4; discussion 234-5. PubMed ID: 16166993
[No Abstract] [Full Text] [Related]
32. Autologous peripheral blood stem cell transplantation to treat CHOP-refractory aggressive subcutaneous panniculitis-like T cell lymphoma.
Nakahashi H; Tsukamoto N; Yamane A; Saitoh T; Uchiumi H; Handa H; Karasawa M; Murakami H; Kojima M; Nojima Y
Acta Haematol; 2009; 121(4):239-42. PubMed ID: 19556752
[No Abstract] [Full Text] [Related]
33. Successful allogeneic stem cell transplantation for an adult with refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Chen CH; Chen SW; Shen WL; Chen TY; Tsao CJ; Huang WT
Int J Hematol; 2007 Feb; 85(2):105-7. PubMed ID: 17321986
[TBL] [Abstract][Full Text] [Related]
34. Secondary CNS involvement of ALK-negative anaplastic large cell lymphoma.
Major A; Pan Z; Kamdar M
Am J Hematol; 2017 Nov; 92(11):1267-1268. PubMed ID: 28370436
[No Abstract] [Full Text] [Related]
35. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
Shankar A; Hayward J; Kirkwood A; McCarthy K; Hewitt M; Morland B; Daw S
Br J Haematol; 2014 May; 165(4):534-44. PubMed ID: 24754633
[TBL] [Abstract][Full Text] [Related]
36. Incidence and outcome of patients with diffuse large B cell lymphoma with marrow involvement and preliminary experience of an adult acute lymphoblastic leukemia protocol (NEALL VI) in cyclophosphamide, doxorubicin, vincristine, and prednisolone--rituximab refractory patients.
Sieniawski M; Bhartia S; Wilkinson J; Proctor SJ
Leuk Lymphoma; 2009 Oct; 50(10):1726-30. PubMed ID: 19639513
[No Abstract] [Full Text] [Related]
37. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
[TBL] [Abstract][Full Text] [Related]
38. A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxorubicin.
Trucco M; Barredo JC; Goldberg J; Leclerc GM; Hale GA; Gill J; Setty B; Smith T; Lush R; Lee JK; Reed DR
Pediatr Blood Cancer; 2018 Sep; 65(9):e27224. PubMed ID: 29856514
[TBL] [Abstract][Full Text] [Related]
39. [Clinical features and prognosis for anaplastic large cell lymphoma].
Dong F; Liu Y; Li Q; Wang J; Jing H; Ke X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Jun; 43(6):631-637. PubMed ID: 30110005
[TBL] [Abstract][Full Text] [Related]
40. Early and sustained remission with brentuximab vedotin in a case of disseminated cutaneous relapse from systemic anaplastic large cell lymphoma refractory to chemotherapy.
Aguiar-Bujanda D; Dueñas-Comino A; Cabello C; Bastida J; Rivero-Vera JC; Limeres-González MA
Eur J Dermatol; 2017 Dec; 27(6):671-673. PubMed ID: 29165301
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]